Search Login Register

omalizumab (Xolair) Summary

Description: a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding

Also Known As: Xolair; Novartis Brand of Omalizumab

Networked: 892 relevant articles (247 outcomes, 239 trials/studies) for this Drug

Key Diseases for which omalizumab is Relevant

  1. Asthma (Bronchial Asthma) : 177 outcomes 188 studies in 590 results
  2. Urticaria (Hives) : 41 outcomes 27 studies in 153 results
  3. Rhinitis : 16 outcomes 17 studies in 57 results
  4. Seasonal Allergic Rhinitis (Hay Fever) : 8 outcomes 5 studies in 27 results
  5. Atopic Dermatitis (Atopic Eczema) : 7 outcomes 7 studies in 37 results
Show All >>

Drugs Related to omalizumab

  1. anti-IgE
  2. Immunoglobulin E (IgE)
  3. Adrenal Cortex Hormones (Corticosteroids)
  4. omalizumab (Xolair)
  5. Histamine Antagonists (Antihistamines)
  6. Steroids
  7. Immunoglobulin G (IgG)
  8. Immunoglobulins (Immunoglobulin)
  9. Prednisolone (Predate)
  10. Prednisone (Sone)
Show All >>

Therapies Related to omalizumab

  1. Immunotherapy
  2. Aftercare (After-Treatment)
  3. Retreatment
  4. Stents
  5. Drug Therapy (Chemotherapy)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.